Innate Pharma (IPHA) Return on Sales (2020 - 2024)

Innate Pharma has reported Return on Sales for 5 years, with the latest figure at 0.04% in Q4 2024.

• For the quarter ending Q4 2024, Return on Sales fell 4.0% year-over-year to 0.04%; the trailing twelve-month figure through Dec 2024 stood at 0.01% (down 1.0% YoY), and the FY2022 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q4 2024 stood at 0.04%, down from 0.03% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q2 2023, with the low at 0.04% in Q4 2024.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2021 — Return on Sales gained 1 bps — and 2024, when it slipped 4 bps.
• Innate Pharma's Return on Sales stood at 0.01% in 2020, then surged by 74 bps to 0.0% in 2021, then soared by 100 bps to 0.0% in 2022, then tumbled by 6421288 bps to 0.0% in 2023, then slumped by 2587 bps to 0.04% in 2024.
• The last three Return on Sales figures came in at 0.04% (Q4 2024), 0.03% (Q2 2024), and 0.0% (Q4 2023), per Business Quant data.